Skip to content

Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02522091
Acronym
IMPRO
Enrollment
178
Registered
2015-08-13
Start date
2010-11-30
Completion date
Unknown
Last updated
2015-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

Investigators propose in this study to evaluate prospective memory (MP) in all its complexity as well as the processes, cognitive and brain, the underlying. Specifically, investigators propose to evaluate the evolution of the MP during normal aging and Alzheimer's disease (AD) to identify the cognitive and brain processes underlying this development. To do this, this study will have to include healthy subjects, 18 to 95 years, patients with Mild Cognitive Impairment (MCI) and patients with probable AD. All participants will undergo a series of examinations, both neuropsychological and brain imaging.

Interventions

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All participants: * Normal Education\> 7 years * French mother tongue * right-handed (Edinburgh Inventory) * score on the scale of Beck \<7 (depression scale) * signing the informed consent of the protocol in agreement with the Committee to Protect People * Medical examinations, neurological, neuropsychological and neuroimaging depth in accordance with the specific inclusion and

Exclusion criteria

for each population, that is to say: * Young healthy subjects aged between 18 and 44 years * Healthy subjects intermediate age: between 45 and 69 years * score on the Mattis Dementia Scale higher than 137, in order to exclude any potential dementia * Performance normal to test RI RL-16 (that is to say, not differing by more than 1.65 standard deviation from the norm for age and cultural level \[see normative values published Van der Linden et al., 2004\]), test conventionally used to assess the verbal episodic memory. * Healthy elderly subjects aged 70 and over, living at home * score on the Mattis Dementia Scale higher than 137, in order to exclude any potential dementia * Performance normal to test RI RL-16 (that is to say, not differing by more than 1.65 standard deviation from the norm for age and cultural level \[see normative values published Van der Linden et al., 2004\]), test conventionally used to assess the verbal episodic memory. * MCI patients: older than 50 years and recruited from memory clinics and meet the current criteria and recognized including amnestic MCI * memory complaint * targets deficits of episodic memory (lower performance of at least 1 standard deviation from the norm for age and cultural level to one or more (sub) episodic memory scores of diagnostic battery - cf. . Tables 1 and infra) * performance in the standards for age and cultural level in all tests of diagnostic battery measuring other cognitive functions as memory, including the evaluation of overall cognitive ability tests. * Alzheimer's patients: older than 50 years were recruited from the clinics and memory satisfying the standards NINCDS-ADRDA criteria for probable AD which include * abnormal global cognitive functioning and deficits in two or more cognitive domains identified by the diagnostic battery * mild to moderate AD (MMSE ≥ 18).

Design outcomes

Primary

MeasureTime frame
measuring the amplitude of the BOLD signal (Blood Oxygen Level Dependent)baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026